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Introduction
The ANCA-associated vasculitides (AAV) comprise microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA; Wegener's) and eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss). (1, 2) AAV are predominantly diseases of older patients, and the incidence increases with age. (3, 4) Several studies have shown that the risk of death and ESRD is higher in older patients but their response to treatment differs between studies. (5, 6) Because of an increased risk of adverse events,(7) dose adjustments of cyclophosphamide have been made for age in clinical trials (8) and are recommended in guidelines. (9) Despite the fact that AAV commonly affect older patients, the outcome of MPA and GPA in the elderly population is largely unknown.(10) Many randomized trials exclude patients aged >75 years and there are few observational studies focusing on elderly patients. (11, 12) The aim of this study was to investigate demographic factors, treatment and outcome in patients aged ≥75 years presenting with MPA or GPA.
Materials and Methods

Case retrieval and classification
Consecutive patients presenting at six centers in Sweden, United Kingdom 
Participating centers
The Swedish cohort was recruited from local vasculitis databases at the Nephrology and Rheumatology Departments at Linköping University Hospital (catchment area 430 000 inhabitants) (14) , the Nephrology and Rheumatology Departments at Skåne University Hospital in Lund and Malmö (700 000 inhabitants)(3) and the Nephrology Department at Karolinska University Hospital (1.5 million inhabitants).
The English cohort was recruited from a local database at the Imperial College Renal and Transplant Centre (2 million inhabitants) and from vasculitis and renal pathology databases at the Nephrology Department at Royal Free Hospital (1.4 million inhabitants) in London.
The Czech cohort was recruited from the Department of Nephrology at General University Hospital in Prague (tertiary national referral center with catchment area for vasculitis about 5 million inhabitants), using a local database transferred into a nationwide registry in 2009.
Data collection
The following data were collected retrospectively from time of diagnosis: date of diagnosis, age, sex, diagnosis type (MPA/GPA), ANCA specificity, C-reactive protein, creatinine (at diagnosis or before start of dialysis in patients dialysis dependent at diagnosis), dialysis dependency, disease activity according to Birmingham Vasculitis Activity Score (BVAS) (15) and major comorbidities. Data on outcome up to 2 years from diagnosis included day of death and ESRD. Data on treatment during the first 3 months from diagnosis included cumulative dose of pulse steroids, oral steroids and cyclophosphamide, treatment with rituximab or other cytotoxic agents, and use of plasma exchange. Based on the treatment issued during the first month, patients surviving that point were divided into groups. Patients were assigned to the rituximab group if they were receiving any dose of rituximab. Patients were assigned to the oral cyclophosphamide group or the intravenous cyclophosphamide group if they were issued a minimum cumulative dose of 2000 mg oral or 1500 mg intravenous cyclophosphamide, respectively, during the first 3 months. Patients who were given less cyclophosphamide or treated with azathioprine, mycophenolate or methotrexate were assigned to "other regimens" group, whereas patients were assigned to the "steroids only" group if they were given a daily dosage of ≥30 mg of prednisolone. The remaining patients were placed in the "untreated" group. For each group, the proportion of patients given pulse steroids (cumulative dose ≥250 mg) or plasma exchange was recorded. The effect of treatment on survival and renal survival was estimated using an intention-to-treat approach starting on day 30.
Date of diagnosis was defined as follows: start of treatment with prednisolone ≥30 mg/day, plasma exchange or cyclophosphamide; if never treated, the day of biopsy; and if no biopsy, the day of the first positive ANCA test result. A dipstick value of ≥2 was taken as representative of hematuria equal to 10 red blood cells per high-power field when assessing BVAS. Indirect immunofluorescence or antigen-specific ELISA was used to detect ANCA.
ESRD was defined as need for dialysis for >90 days. Comorbidities were registered essentially as described by Davies et al(16) with 1 point each given for malignancy, ischemic heart disease, peripheral vascular disease, heart failure, diabetes, systemic inflammatory disease (excluding AAV), pulmonary disease and cirrhosis.
Statistical analyses
Statistical analysis was performed using SPSS Statistics for Windows software (version 21.0; IBM Corp., Armonk, NY). P-values <0.05 were considered significant. Double-positive patients were designated as having either myeloperoxidase-ANCA (MPO-ANCA)/perinuclear ANCA (P-ANCA) or proteinase-3-ANCA (PR3-ANCA)/cytoplasmic ANCA (C-ANCA) depending on the highest titer. Differences between groups were analyzed using the Mann-Whitney or Kruskal-Wallis test for non-parametric data and the chi-squared or Fisher's exact test for categorical data. All analyses exclude missing data. The KaplanMeier method was used to estimate overall and renal survival, and the log-rank test used to evaluate differences between groups. Censoring was performed at the day of loss to or completion of follow-up. Estimates of renal survival were censored for death. In analysis of treatment, patients who died within the first 30 days after diagnosis were excluded. Cox 
Results
Baseline patient characteristics
A total of 151 patients were included in this study, and their characteristics at diagnosis are shown in Table 1 . Median age at diagnosis was 79 years (interquartile range [IQR] 77-82).
MPA was diagnosed in 70% of the patients and GPA in 30%. MPO-ANCA/P-ANCApositivity was seen in 60%, PR3-ANCA/C-ANCA-positivity in 36%, double-positivity in 1%
and ANCA negativity in 3%. Renal involvement (according to BVAS) was seen in 92% of the patients, more commonly in patients with MPA (P<0.001). Biopsy was performed in 113 patients (76.4%; data missing in three patients), of these 96 (85.0%) were renal biopsies.
Most parameters showed no significant differences between the three participating countries.
However, dialysis dependency at diagnosis was seen in 16% in the Swedish cohort, compared to 44% in the English cohort and 60% in the Czech cohort (P<0.001). Comorbidities were more common in Czech patients; only 16% had no comorbidities compared to 47% and 40% of the Swedish and English patients, respectively (P<0.001). Median BVAS was 12 (IQR 9-12) in patients with renal-limited disease and 16 (IQR [13] [14] [15] [16] [17] [18] [19] in patients with more than one organ system involved (P<0.001).
Treatment
In total, seven patients died during the first month, and an additional 14 were excluded because of insufficient treatment data, leaving 130 patients for analysis of treatment.
Characteristics for the different treatment groups are shown in Table 2 . There were no significant differences between patients receiving standard immunosuppressive therapy (oral cyclophosphamide, intravenous cyclophosphamide, and rituximab groups) and those not receiving such therapy (other regimens, steroids only, or untreated groups) with regard to creatinine, BVAS, proportion of dialysis dependency, or proportion of patients with at least one comorbid condition at diagnosis. Likewise, there were no significant differences between the participating countries (Supplemental Table S1 ). The median cumulative dose of intravenous cyclophosphamide during the first 3 months in the standard treatment group was 3000 mg (IQR 2100-4500) and the corresponding figure for oral cyclophosphamide was 5270 mg (IQR 3100-6950).
Survival
Patients were followed until 2 years after diagnosis or death. Six patients (all from England) were lost to follow-up, within a median time of 69 days (IQR 34-140). One-year overall survival was 71.5% and 2-year survival 64.6%. During the first 3 months after diagnosis 22 patients (14.6%) died. Older age, higher creatinine and lower BVAS at diagnosis were independent factors associated with higher mortality by univariable ( Figure 1 ; Supplemental 
Discussion
In this study, we show that AAV in older patients is a severe condition with high mortality and morbidity during the first year after diagnosis. Despite the significant burden of disease, we found a relatively favorable outcome for those who survive the first year. To our knowledge, this is the largest study of patients ≥75 years with AAV.
We found older age, high creatinine and low BVAS to be predictors of worse survival. High age and impaired renal function have previously been shown to predict mortality in younger age groups as well. (6, 11, 14, (17) (18) (19) (20) The inverse relationship between BVAS and survival is intriguing and opposite of some previous findings. (11, 18) Because the vast majority of patients in our study had renal involvement at diagnosis, patients with a high BVAS had both renal and extrarenal symptoms, whereas those with renal-limited disease fell in the low BVAS group. It is possible that patients with few extra-renal symptoms are diagnosed at a later stage with more irreversible renal damage and worse survival. However, this association needs to be confirmed in other studies and the cause remains to be elucidated.
Survival was significantly worse in those not treated with standard doses of cyclophosphamide or rituximab. There is a risk of confounding by indication when analyzing treatment data in retrospective studies (in this case, that frail patients receive less treatment), and we did not have data on the detailed clinical context including the goals and preferences of patients or the treating physician's motive for therapy decisions. To reduce this effect we did not include deaths occurring during the first month and used an intention-to-treat approach, reasoning that standard therapy given during the first month was intended to continue according to modern guidelines,(9, 21) whereas this was not the case when such therapy was not issued during the first month. It is, however, difficult to rule out the possibility that some patients who originally received immunosuppressive treatment developed complications and that therapy was stopped. The worse prognosis in these patients would thus be caused by early adverse events. However, also when considering all cyclophosphamide use as intention-to-treat with standard therapy, there was a clear survival benefit for standard therapy. The unfavorable prognosis in those treated less aggressively cannot readily be explained by more comorbidities, worse renal function or differences in disease activity at diagnosis, because these parameters did not differ significantly between the groups. However, this does not exclude the possibility that some patients were still considered frail and not suitable for immunosuppressive therapy. The best survival was seen in patients treated with rituximab; however the number of patients was rather small and no rituximab was given in the Czech cohort with the worst survival rate. Hence, this result should be interpreted with care
The survival differences between countries may, at least partly, be explained by selection bias. The Department of Nephrology in Prague is a tertiary referral center receiving the most severe cases of AAV. Additionally, the Czech patients had more comorbidities and more often had advanced renal insufficiency at diagnosis. Opposite to our results, others have reported dialysis at diagnosis to be an independent factor for survival (20) and it is possible that our analysis did not fully compensate for this factor. Comorbidities were not associated with mortality in the entire cohort, but reached borderline significance in the analysis including treatment. In our cohort, 15% of the patients had a previous malignancy before the diagnosis of AAV. This is similar to other studies showing a frequency of malignancies of 8- One-year survival was 72% and 2-year survival was 65% in this study compared with 82-88% and 82-85%, respectively in previous studies. (2, 17, 18) We also show that survival in the Swedish cohort was significantly worse compared to the background population during the first year after diagnosis, but was not significantly worse during the second year. Together with the fact that no new cases of ESRD occurred during the second year, this implies a fairly good prognosis if patients survive the first year.
Importantly, we found that elderly patients usually present with significant renal involvement and a predominance of clinical MPA and MPO-ANCA/P-ANCA positivity. This is consistent with the finding that patients with MPA are older than patients with GPA and that patients with MPO/P-ANCA are older than patients with PR3/C-ANCA. (5, 6, 11, 18, 24, 25) Results showing that older patients with GPA have more renal insufficiency and less upper airway symptoms (26) add to this picture. We found a higher proportion of MPO/P-ANCA positive GPA as compared to two large studies in Caucasian patients. In our cohort, 24% of patients with GPA were positive for MPO/P-ANCA compared with 9% and 10%, respectively, in a follow-up of patients from four European Vasculitis Study Group trials and a large genetic study in Europe. (18, 27) High creatinine at presentation is a well-known risk factor for impaired renal survival (2, 12, 17, 28, 29) , and we confirmed this in older patients. High creatinine at diagnosis was the only significant predictor of renal survival in multivariable analysis, and treatment with immunosuppressive agents was not significantly associated with renal survival. Most patients reaching ESRD were dialysis dependent at presentation and conceivably already had (76) 50% (75) 55% (48) 45% (39) 54% (21) 46% (18) 28% (7) 72% (18) 0.05 47% (49) 53% (56) 59% (27) 41% ( (82) 46% (69) 52% (45) 48% (42) 56% (22) 44% (17) 60% (15) 40% (10) 0.73 51% (54) 49% (51) 61% (28) 39% (18) 0.28
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